Evidence map›Paper›PMID 39549152›Full record

ArticleInfectious diseases and therapy2025

Leveraging Real-World Evidence to Define Severe RSV Lower Respiratory Tract Disease in Adults.

Catherine A Panozzo, Edward E Walsh, Zhen Yang, Eleanor Wilson, Jaya Goswami, Sonia K Stoszek, Adrianna Loback, Tony Ng, Beverly M Francis, Alana K Simorellis and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infectious diseases and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Catherine A PanozzoInfectious Disease Clinical Development, Moderna, Inc., 325 Binney Street, Cambridge, MA, 02142, USA. Catherine.Panozzo@modernatx.com.
Edward E WalshDepartment of Medicine, University of Rochester, Rochester, NY, USA.
Zhen YangData Science and Artificial Intelligence, Moderna, Inc., Cambridge, MA, USA.
Eleanor WilsonInfectious Disease Clinical Development, Moderna, Inc., 325 Binney Street, Cambridge, MA, 02142, USA. Eleanor.Wilson@modernatx.com.
Jaya GoswamiInfectious Disease Clinical Development, Moderna, Inc., 325 Binney Street, Cambridge, MA, 02142, USA.
Sonia K StoszekInfectious Disease Clinical Development, Moderna, Inc., 325 Binney Street, Cambridge, MA, 02142, USA.
Adrianna LobackData Science and Artificial Intelligence, Moderna, Inc., Cambridge, MA, USA.
Tony NgData Science and Artificial Intelligence, Moderna, Inc., Cambridge, MA, USA.
Beverly M FrancisMedical Affairs, Moderna, Inc., Cambridge, MA, USA.
Alana K SimorellisInfectious Disease Clinical Development, Moderna, Inc., 325 Binney Street, Cambridge, MA, 02142, USA.
Wenmei HuangClinical Development Operations, Moderna, Inc., Cambridge, MA, USA.
Linwei LiInfectious Disease Clinical Development, Moderna, Inc., 325 Binney Street, Cambridge, MA, 02142, USA.
Rebecca Vislay-WadeData Science and Artificial Intelligence, Moderna, Inc., Cambridge, MA, USA.
Zhe ZhengInfectious Disease Clinical Development, Moderna, Inc., 325 Binney Street, Cambridge, MA, 02142, USA.
Evan J AndersonInfectious Disease Clinical Development, Moderna, Inc., 325 Binney Street, Cambridge, MA, 02142, USA.
Allison AugustInfectious Disease Clinical Development, Moderna, Inc., 325 Binney Street, Cambridge, MA, 02142, USA.
Grace ChenInfectious Disease Clinical Development, Moderna, Inc., 325 Binney Street, Cambridge, MA, 02142, USA.
Ann R FalseyDepartment of Medicine, University of Rochester, Rochester, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAs no standard case definitions for respiratory syncytial virus-associated lower respiratory tract disease (RSV-LRTD) in adults are available, this study analyzed definitions for severe RSV-LRTD from previously published data in hospital and community cohorts of adults with RSV-associated symptoms.

methodsThe frequency, sensitivity, and specificity of acute respiratory disease symptoms among hospitalized and community cohorts of adults with RSV were analyzed. RSV-LRTD signs/symptoms assessed included shortness of breath (dyspnea), cough and/or fever, wheezing/rales/rhonchi (abnormal lung sounds by auscultation), sputum production, tachypnea, hypoxemia, and pleuritic chest pain.

resultsDyspnea and tachypnea provided the best differentiation between hospitalized and community RSV-positive cases. The severe RSV-LRTD case definition yielding one of the highest and best-balanced sensitivity and specificity was dyspnea paired with either abnormal lung sounds by auscultation, hypoxemia, tachypnea, cough and/or fever, sputum, or chest pain.

conclusionsDyspnea alone, and in combination with certain other lower respiratory tract disease signs/symptoms, was a leading symptomatic indicator for severe RSV outcomes. These results contribute to the harmonization of case definitions for RSV disease.

Indexed as

Case definitionsLower respiratory tract diseaseOlder adultsRespiratory syncytial virusSevere respiratory syncytial virus

Identifiers

PMID39549152
PMCPMC11782790

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.